NO20043786L - Antidepresjonsmiddel - Google Patents

Antidepresjonsmiddel

Info

Publication number
NO20043786L
NO20043786L NO20043786A NO20043786A NO20043786L NO 20043786 L NO20043786 L NO 20043786L NO 20043786 A NO20043786 A NO 20043786A NO 20043786 A NO20043786 A NO 20043786A NO 20043786 L NO20043786 L NO 20043786L
Authority
NO
Norway
Prior art keywords
gen
acyl
substituted
benzofused
protein kinase
Prior art date
Application number
NO20043786A
Other languages
English (en)
Norwegian (no)
Inventor
Masaomi Miyamoto
Shigenori Ohkawa
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20043786L publication Critical patent/NO20043786L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/4035—Isoindoles, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/443—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Compounds Of Unknown Constitution (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NO20043786A 2002-03-01 2004-09-09 Antidepresjonsmiddel NO20043786L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2002055771 2002-03-01
JP2002195434 2002-07-04
PCT/JP2003/002293 WO2003074046A1 (fr) 2002-03-01 2003-02-28 Antidepresseur

Publications (1)

Publication Number Publication Date
NO20043786L true NO20043786L (no) 2004-09-09

Family

ID=27790932

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20043786A NO20043786L (no) 2002-03-01 2004-09-09 Antidepresjonsmiddel

Country Status (13)

Country Link
US (2) US20050148650A1 (de)
EP (1) EP1481679B1 (de)
JP (1) JP2010111698A (de)
KR (1) KR101011657B1 (de)
CN (1) CN1638763A (de)
AT (1) ATE478666T1 (de)
AU (1) AU2003211261A1 (de)
CA (1) CA2477903C (de)
DE (1) DE60333902D1 (de)
HK (1) HK1070273A1 (de)
NO (1) NO20043786L (de)
PL (1) PL371366A1 (de)
WO (1) WO2003074046A1 (de)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7652191B2 (en) 2003-03-19 2010-01-26 Bar Ilan University Nonhuman mammals exhibiting PTSD-like behavior
JP2010509188A (ja) * 2006-11-09 2010-03-25 武田薬品工業株式会社 医薬組成物
ES2390004T3 (es) * 2008-01-30 2012-11-05 Cephalon, Inc. Derivados sustituidos de piperidina espirocíclica como ligandos del receptor de la histamina 3(H3)
UY32481A (es) * 2009-03-10 2010-09-30 Takeda Pharmaceutical Derivados de benzofurano
US8828924B2 (en) * 2009-05-14 2014-09-09 University Of Maryland, Baltimore Methods of treating a diabetic embryopathy
WO2013035826A1 (ja) * 2011-09-08 2013-03-14 武田薬品工業株式会社 縮合複素環化合物
US11071793B2 (en) * 2014-08-29 2021-07-27 Chdi Foundation, Inc. Probes for imaging huntingtin protein
WO2018172527A1 (en) * 2017-03-24 2018-09-27 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical composition for the treatment of neurodegenerative disease
EP4367112A1 (de) 2021-07-09 2024-05-15 Plexium, Inc. Arylverbindungen und pharmazeutische zusammensetzungen zur modulierung von ikzf2

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4799934A (en) 1987-10-30 1989-01-24 Clairol Incorporated Sulfur-containing nitroaminobenzene dyes, process and hair dye compositions
EP0539709A1 (de) * 1991-09-18 1993-05-05 FUJIREBIO Inc. 3,5-Dihydroxyheptansäurederivate und deren Lactone als HMG-CoA-Reduktase-Inhibitoren
CA2214247C (en) 1995-03-14 2004-02-10 Praecis Pharmaceuticals Incorporated Modulators of amyloid aggregation
EP0929574B1 (de) 1996-08-27 2005-06-29 Praecis Pharmaceuticals Incorporated beta-AMYLOID PEPTIDAGGREGATION REGULIERENDE PEPTIDE MIT D-AMINOSÄUREN
CA2291026A1 (en) 1997-06-05 1998-12-10 Takeda Chemical Industries, Ltd. Heterocyclic compounds, their production and use
JPH1149765A (ja) * 1997-06-05 1999-02-23 Takeda Chem Ind Ltd 複素環化合物、その製造法および剤
ES2234300T3 (es) 1998-10-08 2005-06-16 Smithkline Beecham Plc 3-(3-cloro-4-hidroxifenilamino)-4-(2-nitrofenil)-1h-pirrol-2,5-diona como inhibidor de glucogeno cinasa-3 (gsk-3)sintetasa.
KR100660788B1 (ko) 1998-12-04 2007-02-28 다케다 야쿠힌 고교 가부시키가이샤 벤조푸란 유도체, 그 제조법 및 용도
AU5773500A (en) 1999-06-28 2001-01-31 Board Of Trustees Of The University Of Illinois, The Inhibitors of memapsin 2 and use thereof
JP2002201172A (ja) * 2000-02-25 2002-07-16 Japan Tobacco Inc ベンズアミド誘導体及びその用途
WO2001068666A1 (en) * 2000-03-14 2001-09-20 Thomas Jefferson University Tcl1 enhances akt kinase activity and mediates its nuclear translocation
GB0022333D0 (en) 2000-09-12 2000-10-25 Glaxo Group Ltd Methods for identifying modulators of protein interactions
JP2002348239A (ja) 2000-10-05 2002-12-04 Takeda Chem Ind Ltd 幹細胞・神経前駆細胞の増殖・分化促進剤
US20040034049A1 (en) * 2000-10-05 2004-02-19 Shigenori Okawa Promoters for the proliferation and differentiation of stem cells and/or neuron precursor cells
DE60136566D1 (de) * 2000-12-28 2008-12-24 Takeda Pharmaceutical Verfahren zur herstellung von optisch aktiven 2,4-dihydrobenzofuranverbindungen
US7153871B2 (en) * 2001-01-22 2006-12-26 Memory Pharmaceuticals Corporation Phosphodiesterase 4 inhibitors, including aminoindazole and aminobenzofuran analogs
US6566550B2 (en) * 2001-06-21 2003-05-20 Pfizer Inc Substituted aromatic ethers as inhibitors of glycine transport
EP1411052B1 (de) * 2001-07-05 2011-10-05 Takeda Pharmaceutical Company Limited Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung

Also Published As

Publication number Publication date
KR101011657B1 (ko) 2011-01-28
KR20040096636A (ko) 2004-11-16
US20050148650A1 (en) 2005-07-07
HK1070273A1 (en) 2005-06-17
JP2010111698A (ja) 2010-05-20
US7750037B2 (en) 2010-07-06
CA2477903A1 (en) 2003-09-12
EP1481679A4 (de) 2005-11-23
CN1638763A (zh) 2005-07-13
EP1481679A1 (de) 2004-12-01
US20060241168A1 (en) 2006-10-26
EP1481679B1 (de) 2010-08-25
WO2003074046A1 (fr) 2003-09-12
AU2003211261A1 (en) 2003-09-16
DE60333902D1 (de) 2010-10-07
CA2477903C (en) 2010-10-12
PL371366A1 (en) 2005-06-13
ATE478666T1 (de) 2010-09-15

Similar Documents

Publication Publication Date Title
HK1070273A1 (en) Antidepressant
MY125506A (en) Benzodiazepine derivatives as metabotropic glutamate receptor antagonists
DE69528257D1 (de) KONDENSIERTE HETEROCYCLISCHE VERBINDUNG, DEREN HERSTELLUNG UND VERWENDUNG ALS GnRH ANTAGONISTEN
CA2383555A1 (en) 3(5)-amino-pyrazole derivatives, process for their preparation and their use as antitumor agents
DK1680418T3 (da) Derivater af N-(heteroaryl-(piperidin-2yl)methyl)benzamid, deres fremstilling og deres anvendelse som terapeutika
BR9814548A (pt) "derivados de alfa-aminoamida úteis como agentes analgésicos"
EP1312601A4 (de) Carbonsäurederivate, verfahren zu deren herstellung und medikamente, die diese als wirkstoff enthalten
DE69615682D1 (de) N-(1-alkyl-5-phenyl-2,3,4,5-tetrahydro-1-h-benzo[b][1,5]-diazepin-3-yl)-acetamide
WO2003082847A1 (fr) Derive de benzofurane
ATE527247T1 (de) Benzokondensierte 5gliedrige heterocyclische verbindungen, verfahren zu deren herstellung und deren verwendung
ATE347356T1 (de) Hydroxamsäurederivate als antibakterielle arzneimittel
UY25636A1 (es) Proceso para la preparacion de compuestos azopoliciclicos condensados
TR199900477T2 (xx) Thiazolil-alanin art��� ihtiva eden yeni peptid t�revleri.
EP1589018A4 (de) Herstellungsverfahren für hexahydrofurofuranol-derivate, zwischenprodukt davon und herstellungsverfahren dafür
DE69625709D1 (de) Alpha-substituierte heterozyklische benzylderivate, zwischenverbindungen zu ihrer herstellung und pestizide die diese als aktiver bestandteil enthalten
PT1165485E (pt) Processo para a preparacao de produtos intermediarios pesticidas
AU6594900A (en) Tricyclic dihydrobenzofuran derivatives, process for the preparation thereof andagents
BR9307232A (pt) 4-Estrenos ligados por meio de ponte-19,11 com efic cia gestag-nica
BR9611572A (pt) Produção de um sal de ácido clavulânico
DE69608699D1 (de) Fluorsubstituierte benzoylpropionsaürederivate
WO1995002603A3 (en) Use of cephem derivatives as anti-metastatic agents
AU6595000A (en) Dihydrobenzofuran derivatives, process for the preparation thereof and agents
DE60021109D1 (de) Amycomycin, verfahren zu dessen herstellung und seine verwendung als arzneimittel
AR042740A1 (es) Diazepanes farmaceuticamente activos
ES2150073T3 (es) Nuevos agentes fungicidas ll-15g256gamma, delta y epsilon, producidos por el ll-15g256 (hypoxylon oceanicum).

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application